T2DM Focused Update: SGLT2 Inhibitors & GLP1 Agonists

Last updated on March 5, 2024
Personalized education in 30-60 minutes either in-person visit or web conferencing (e.g., Zoom or WebEx) at a time that is convenient for you. This Group Learning program has been certified by the College of Family Physicians of Canada and the British Columbia Chapter for up to 1 Mainpro+ credits.

Learning objective

Participants will be able to thoughtfully discuss, prescribe and monitor the SGLT2 inhibitors and GLP1 agonists for people with type 2 diabetes.

During each academic detailing session, participants will have the opportunity to:

  • Discuss changes to available evidence and clinical practice guidelines which inform medication choices beyond HbA1c lowering.
  • Review clinical considerations which support treatment decisions including: doses, adverse events, dosage forms, cost and coverage.
  • Specifically discuss the three most commonly prescribed in British Columbia: empagliflozin, semaglutide subcutaneous, canagliflozin.

After the academic detailing session, participants will be able to:

  1. Consider how changes to the available evidence inform medication choices for cardiovascular, kidney and mortality outcomes.
  2. Identify the clinical outcomes where confident medication choices cannot yet be made.
  3. Apply evidence from longer term clinical trials and observational studies which inform dosing and monitoring for adverse events.


When: Until August 10, 2024
Where: In-person at your place of work or virtual academic detailing
How: Contact your local PAD pharmacist directly or email PAD@gov.bc.ca 


For more information about the PAD service, visit the Provincial Academic Detailing page.